Clinical Trials
10 trialsNCT00003060 2020-06-30
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
Louisiana State University Health Sciences Center Shreveport
Phase 1 Terminated
NCT01408043 2019-06-14
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase NA Terminated
NCT00290628 2017-11-29
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT01076270 2017-06-28
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase NA Terminated
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00704938 2015-10-28
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00005852 2012-12-11
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00253552 2012-05-28
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
OHSU Knight Cancer Institute
Phase NA Terminated
NCT00138229 2012-03-29
Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated